Type 2 Diabetes Carries 53% Higher Alzheimer’s Risk, Review Finds

People with type 2 diabetes face a 53% higher adjusted relative risk of developing Alzheimer’s disease, a systematic review and meta-analysis published in the journal Alzheimer’s Research & Therapy found.

The study, titled “Incidence and risk of Alzheimer’s disease in individuals with type 2 diabetes: a systematic review and meta-analysis,” aims to provide a more precise understanding of risk factors for this population.

Researchers from Curtin University analyzed data from 40 studies to determine the connection between the two conditions. Their findings, as reported by ScienceDaily, estimate that for every 1,000 people living with type 2 diabetes, approximately 4.7 individuals will develop Alzheimer’s disease within a single year. According to a statement released by the university on Thursday, this quantitative assessment helps clarify the disease burden.

Type 2 diabetes associated with 53% higher Alzheimer’s risk, with claims data likely undercounting cases, review shows
Photo: Managed Healthcare Executive

“While many earlier reviews combined different types of diabetes or dementia, this review focused specifically on type 2 diabetes and Alzheimer’s disease and estimated how often new cases occurred,” said Dr. Emmanuel Adewuyi, an NHMRC Investigator Fellow at the Curtin School of Population Health.

Dr. Adewuyi noted that the research provides a clearer view of the disease burden for clinicians and health systems. “Relative risk tells us how two groups compare, while incidence tells us how often new cases occur: putting those numbers together gives us a clearer picture of the burden of Alzheimer’s disease among people living with type 2 diabetes,” he told ScienceDaily.

Link Between Type 2 Diabetes and Alzheimers? #type2diabetes #alzheimer #shorts #news #health — Medical Dialogues

The study authors suggested that variations in glucose-lowering medications across the analyzed studies may influence dementia outcomes. According to Managed Healthcare Executive, researchers cited observational evidence associating metformin, pioglitazone, and acarbose with lower dementia risk.

Additional evidence suggests that GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors may also correlate with reduced risk, though these findings remain observational. The authors noted that these estimates could serve as a reference point for future research testing whether treating metabolic disease alters a patient’s odds of developing Alzheimer’s.

Health systems face major consequences because both conditions often strike the same older, high-cost patients. Data from the Alzheimer’s Association indicates that more than 7 million Americans are currently living with Alzheimer’s, with total annual care costs estimated at $409 billion, Managed Healthcare Executive reported. Meanwhile, the CDC estimates that 12% of the U.S. population has diabetes, a figure that includes approximately 11 million undiagnosed adults.

Photo: Newswav

“While relative risks are valuable for etiological inference, incidence rates provide a direct measure of disease burden that is highly relevant for risk stratification, prevention planning and health-system forecasting,” the research team wrote in the study.